Publications by authors named "Vanessa F Moreira Ferreira"
Article Synopsis
- The study investigates how well serum biomarkers, specifically neurofilament light (sNfL) and glial fibrillary acidic protein (sGFAP), can detect contrast-enhancing magnetic resonance imaging (MRI) lesions in multiple sclerosis patients.
- The research involved 557 patients, analyzing their MRI results and biomarker levels, finding that high levels of sNfL are somewhat effective at predicting the presence of MRI lesions, particularly in younger patients.
- Though elevated sNfL levels can indicate a likelihood of lesions, low levels do not eliminate the necessity for MRI scans for accurate diagnosis.
Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis.
Mult Scler J Exp Transl Clin
April 2021
Background: There is limited data analyzing the safety and effectiveness of dimethyl fumarate (DMF) in the progressive multiple sclerosis (PMS) population.
Objective: To analyze the safety and effectiveness of DMF in patients with PMS.
Methods: We used Cox proportional hazards models to compare the time to confirmed worsening and improvement on the Expanded Disability Status Scale (EDSS) and timed 25-foot walk (T25FW) between patients treated with DMF and glatiramer acetate (GA) for at least one year.
Objectives: To explore the safety and efficacy profile of teriflunomide in progressive multiple sclerosis.
Methods: We conducted a single-center retrospective observational analysis of a progressive multiple sclerosis population, assessing safety and efficacy in patients treated at least one year with teriflunomide or glatiramer acetate. Sustained progression of expanded disability status scale and sustained worsening of timed 25-foot walk were compared using a Cox proportional hazards model.
A 41-year-old female diagnosed with multiple sclerosis began ocrelizumab treatment. She received her first treatment course without significant complication. After receiving the first maintenance dose 6 months later, she developed weakness, myalgias, gastrointestinal symptoms, headache, and intermittent fever persisting for 4 weeks.
View Article and Find Full Text PDFTumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab.
Neurol Neuroimmunol Neuroinflamm
September 2019